Cargando…

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective

BACKGROUND: The availability of the tyrosine-kinase inhibitor (TKI), imatinib, and later introduction of second generation TKIs, dasatinib and nilotinib, have not only improved clinical outcomes of patients with chronic myeloid leukemia (CML), but also provide multiple therapeutic options for CML pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirji, Ishan, Gupta, Shaloo, Goren, Amir, Chirovsky, Diana R, Moadel, Alyson B, Olavarria, Eduardo, Victor, Timothy W, Davis, Catherine C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851879/ https://www.ncbi.nlm.nih.gov/pubmed/24099272 http://dx.doi.org/10.1186/1477-7525-11-167

Ejemplares similares

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
por: Hirji, Ishan, et al.
Publicado: (2014)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Priapism in Patients with Chronic Myeloid Leukemia (CML): A Systematic Review
por: Ali, Elrazi, et al.
Publicado: (2021)

Appearance and Disappearance of Chronic Myeloid Leukemia (CML) in Patient with Chronic Lymphocytic Leukemia (CLL)
por: Payandeh, Mehrdad, et al.
Publicado: (2014)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia (CML)
por: Frankhouser, David E., et al.
Publicado: (2023)

Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021)

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
por: Şahin, Fahri, et al.
Publicado: (2013)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
por: Mealing, Stuart, et al.
Publicado: (2013)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
por: Adnan Awad, Shady, et al.
Publicado: (2022)

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
por: Sora, Federica, et al.
Publicado: (2021)

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
por: Miranda, M B, et al.
Publicado: (2016)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

Isodicentric Philadelphia chromosome: an uncommon chromosomal abnormality in the chronic phase of chronic myeloid leukemia (CML)
por: Loo, Eric, et al.
Publicado: (2015)

What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
por: Delgado, Nancy, et al.
Publicado: (2022)

How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
por: Guru Murthy, Guru Subramanian
Publicado: (2022)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

PB1986: FIRST-LINE TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN A REAL-WORLD DATA SETTING IN LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
por: Iriyama, Noriyoshi, et al.
Publicado: (2017)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
por: Zizioli, Daniela, et al.
Publicado: (2021)

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
por: Boucher, Lara, et al.
Publicado: (2023)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation
por: Song, Jinming, et al.
Publicado: (2020)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017
por: Daskalakis, Michael, et al.
Publicado: (2021)

PB1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML).
por: Fernandez-Leyva, Harberth
Publicado: (2023)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
por: Saussele, Susanne, et al.
Publicado: (2018)

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
por: Sembill, Stephanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1r3gs4b8u2o3760u3nls2ub8b1